|
2024
|
Invention
|
Gsk3a inhibitors and methods of use thereof. Disclosed are compounds and compositions which inhib... |
|
|
P/S
|
Pharmaceutical preparations for treating cancer and mastocytosis |
|
|
P/S
|
Pharmaceutical preparations for treating cancer and mastocytosis |
|
|
Invention
|
Cdk2 inhibitors. The present disclosure provides, in part, a compound represented by structural F... |
|
|
Invention
|
Cdk2 inhibitors.
The present disclosure provides a compound represented by structural Formula (I... |
|
|
Invention
|
Wild type kit inhibitors.
Disclosed is a compound represented by Formula (I) or a pharmaceutical... |
|
|
Invention
|
The cdk2 inhibitor blu-222 for treatment of cancer. The present disclosure provides improved meth... |
|
|
Invention
|
Solid forms of a cdk2 inhibitor. The compound N-(5-(difluoromethoxy)-1H-pyrazol-3-yl)-1-((tetrahy... |
|
2023
|
Invention
|
Compounds and compositions as fgfr3 degraders and uses thereof. Described herein are compounds of... |
|
|
Invention
|
Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1... |
|
|
Invention
|
N-phenyl-pyrazolo[1,5-a]pyridine-3-carboxamide derivatives as wild type c-kit kinase inhibitors f... |
|
|
Invention
|
Egfr inhibitors for treatment of cancer. The present disclosure provides improved methods of trea... |
|
|
Invention
|
Compositions useful for treating disorders related to kit.
Compounds and compositions useful for... |
|
|
Invention
|
Egfr inhibitors. The present disclosure provides a compound represented by structural formula (I)... |
|
|
Invention
|
Methods for treating systemic mastocytosis and gastrointestinal stromal tumors.
The present disc... |
|
|
Invention
|
Salt and crystal forms of an epidermal growth factor receptor inhibitor |
|
|
Invention
|
Salt and crystal forms of an epidermal growth factor receptor inhibitor. Various salt forms and f... |
|
|
Invention
|
Inhibitors of activin receptor-like kinase.
Described herein are compounds that inhibit ALK2 and... |
|
|
Invention
|
Kit inhibitors. One embodiment of the disclosure is a compound represented by Formula (I) or a ph... |
|
|
Invention
|
Egfr inhibitors. The present disclosure provides a compound represented by structural formula (A)... |
|
|
Invention
|
Blu-945 in combination with osimertinib for the treatment of non-small-cell lung cancer. The pres... |
|
|
Invention
|
Cdk2 inhibitors. The present disclosure provides a compound represented by structural Formula (I)... |
|
2022
|
Invention
|
Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1- f][... |
|
|
Invention
|
Cdk2 inhibitors and methods of making and using same.
The present disclosure provides a compound... |
|
|
Invention
|
Cdk2 inhibitors and methods of making and using same. The present disclosure provides a compound ... |
|
|
Invention
|
Map4k1 inhibitors. One embodiment of the disclosure is a compound represented by Formula I or a p... |
|
|
Invention
|
Map4k1 inhibitors.
One embodiment of the disclosure is a compound represented by Formula I or a ... |
|
|
Invention
|
Process for preparing egfr inhibitors.
The present disclosure provides methods of producing a co... |
|
|
Invention
|
Salt and crystal forms of an epidermal growth factor receptor inhibitor.
Various salt and polymo... |
|
|
Invention
|
Pharmaceutical compositions of an epidermal growth factor receptor inhibitor.
The present disclo... |
|
|
Invention
|
Heterocyclic egfr inhibitors for use in the treatment of cancer.
The present disclosure provides... |
|
|
Invention
|
Egfr inhibitors.
The present disclosure provides a compound represented by structural formula (I... |
|
|
Invention
|
Substituted pyrimidinyl-pyrazoles as cdk2 inhibitors.
The present disclosure provides a compound... |
|
|
Invention
|
Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof.
The pre... |
|
|
Invention
|
Salt and solid forms of a kinase inhibitor.
Various salt forms and free base solid forms of Comp... |
|
|
Invention
|
Synthetic methods and intermediates for producing compounds for treating kit- and pdgfra-mediated... |
|
|
Invention
|
Inhibitors of protein kinase a.
Described herein are compounds of Formula (I) and pharmaceutical... |
|
2021
|
Invention
|
Pyrimidine compounds, compositions, and medicinal applications thereof.
The present disclosure r... |
|
|
Invention
|
Compositions and methods for treating kit- and pdgfra-mediated diseases.
The present disclosure ... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of cancer. |
|
|
P/S
|
Administration of financial assistance and reimbursement programs, namely, administration of fina... |
|
2020
|
Invention
|
Treatment of eosinophilic disorders with avapritinib.
The present invention relates to the use o... |
|
|
P/S
|
Pharmaceutical preparations. |
|
|
P/S
|
Pharmaceutical preparations for the treatment of cancer |
|
|
P/S
|
Pharmaceutical preparations for treating cancer and mastocytosis. Providing medical and scientifi... |
|
2019
|
P/S
|
Pharmaceutical preparations for human use. |
|
|
P/S
|
Pharmaceutical preparations for treating cancer and
mastocytosis. |
|
|
P/S
|
Pharmaceutical preparations for treating cancer and mastocytosis. |
|
|
P/S
|
Pharmaceutical preparations for the treatment of cancer. |
|
|
P/S
|
Pharmaceutical preparations for treating cancer and mastocytosis. |
|
|
P/S
|
Pharmaceutical preparations for treating cancer and mastocytosis |
|
|
P/S
|
Business administration of medication reimbursement programs and services. Administration of fina... |
|
|
P/S
|
Business administration of medication reimbursement programs and services.
Financial administrati... |
|
|
P/S
|
Business administration of medication reimbursement programs
and services. Financial administrat... |
|
|
P/S
|
Providing medical and scientific research information in the field of cancer and mastocytosis, an... |
|
|
P/S
|
Business administration of medication reimbursement programs and services Administration of finan... |
|
|
P/S
|
Downloadable electronic publications in the nature of newsletters, brochures, and reports in the ... |
|
2018
|
P/S
|
Downloadable electronic publications in the nature of brochures in the field of cancer research a... |
|
|
P/S
|
Downloadable electronic publications in the nature of brochures, in the field of cancer research ... |
